Irisin and chemerin levels in patients with type 2 diabetes mellitus

Basit Öğe Kaydı
dc.authoridMustafa Ünal / 0000-0001-6640-6298
dc.authorwosidMustafa Ünal / AAC-2476-2022
dc.contributor.authorBalaban Y.A.
dc.contributor.authorYılmaz N.
dc.contributor.authorKalaycı M.
dc.contributor.authorÜnal, Mustafa
dc.contributor.authorTurhan T.
dc.date.accessioned2020-08-30T20:01:35Z
dc.date.available2020-08-30T20:01:35Z
dc.date.issued2019
dc.departmentİstinye Üniversitesi, Hastaneen_US
dc.description.abstractContext. Changes in the secretion of signaling molecules that originates from adipose tissue and inflammation draw attention in the pathogenesis of type 2 DM. Chemerin, one of the signaling molecules of adipose origin, and irisin, defined as the Renaissance of the metabolism, are among these molecules. Objectives. This cross-sectional study was planned in order to compare the values of serum irisin and chemerin levels in patients newly diagnosed with T2DM and in healthy subjects. Subjects and Methods. The study included 41 patients newly diagnosed with T2DM and 49 healthy individuals. The chemistry parameters were analyzed with a biochemistry autoanalyzer, and hormonal parameters were analyzed with an immunoassay analyzer. Plasma irisin and chemerin levels were measured using the enzyme-linked immunosorbent assay method. Results. There was a significant difference between the groups in terms of glucose, HbA1C, Insulin, HOMA-IR and lipid panel results. Irisin levels in the group of patients newly diagnosed with T2DM were lower than in the control group. Chemerin levels in the group of patients newly diagnosed with T2DM were higher than in the control group. Conclusion. Consequently, diabetes-dependent changes in chemerin and irisin concentrations suggest that these two hormones have a role in the pathophysiology of DM. Further studies are required to understand the complex structure of the signaling pathways of chemerin and irisin molecules as well as the physiological importance of these molecules as metabolism regulators especially in humans. © 2019, Acta Endocrinologica Foundation. All rights reserved.en_US
dc.identifier.citationBalaban, Y. A., Yilmaz, N., Kalayci, M., Unal, M., & Turhan, T. (2019). IRISIN AND CHEMERIN LEVELS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. Acta Endocrinologica (Bucharest), 15(4), 442.en_US
dc.identifier.doi10.4183/aeb.2019.442en_US
dc.identifier.endpage446en_US
dc.identifier.issn1841-0987en_US
dc.identifier.issue4en_US
dc.identifier.pmid32377240en_US
dc.identifier.scopus2-s2.0-85089627696en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage442en_US
dc.identifier.trdizinid387218en_US
dc.identifier.urihttps://doi.org/10.4183/aeb.2019.442
dc.identifier.urihttps://hdl.handle.net/20.500.12713/306
dc.identifier.volume15en_US
dc.identifier.wosWOS:000540348500005en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorÜnal, Mustafaen_US
dc.language.isoenen_US
dc.publisherActa Endocrinologica Foundationen_US
dc.relation.ispartofActa Endocrinologicaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAdipokinesen_US
dc.subjectChemerinen_US
dc.subjectDiabetes Mellitusen_US
dc.subjectIrisinen_US
dc.titleIrisin and chemerin levels in patients with type 2 diabetes mellitusen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
37s.pdf
Boyut:
365 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
İSÜ Hastaneleri Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu